PRA023 has tremendous possibilities for IBD and beyond

Our lead therapeutic candidate, PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis.

We’re now developing PRA023 for the treatment of ulcerative colitis and Crohn’s disease, along with companion diagnostic products designed to help predict responses to identify the right patients for PRA023 with the goal of ensuring maximal response.  

Our biomarker-targeted therapeutic approach has the potential to advance a treatment paradigm similar to that pioneered in oncology, where the push for precision and increasingly targeted treatment has led to therapeutic decision-making based upon a patient’s biomarker profile—and transformed patient outcomes.



Opening up new possibilities by inhibiting TL1A activity
Currently in Phase 2 + Phase 1 trials with great potential in multiple indications*
Designed to transform the treatment paradigm in IBD and beyond

*PRA023 in Phase 2 trials for ulcerative colitis and Phase 1 for Crohn’s disease.

Learn more about TL1A